-
Mashup Score: 151ERN ReCONNET–SLICC–SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations - 2 day(s) ago
Existing guidelines for systemic lupus erythematosus (SLE) predominantly focus on common and major organ involvements. An international taskforce involving experts from three SLE expert groups (ie, the European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases, the Systemic Lupus Erythematosus International Collaborating Clinics group, and the European Lupus Society) was established. A total of 119 participants contributed to the development of consensus therapeutic strategies for 24 rare SLE manifestations, using a multistep process.
Source: www.thelancet.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 1Hydroxychloroquine use in pregnant women with systemic lupus erythematosus: the pill that shields - 2 day(s) ago
Although pregnancy outcomes for women with systemic lupus erythematosus (SLE) have improved, adverse pregnancy outcomes remain frequent. Adverse pregnancy outcomes driven by abnormal placentation (manifesting as pre-eclampsia, eclampsia, or fetal growth restriction), are among the most frequent and concerning adverse outcomes in pregnant women with SLE as they lead to increased fetal, neonatal, and maternal morbidity and mortality.1,2 One of the main recommendations in the management of pregnant women with SLE is to prevent SLE-related damage (such as irreversible organ lesions) before pregnancy and to keep SLE activity low.
Source: www.thelancet.comCategories: General Medicine News, RheumatologyTweet-
Hydroxychloroquine use in pregnant women with systemic #lupus erythematosus: the pill that shields Linked Comment by @GregoireMDF, Gaëlle Guettrot-Imbert, & @nathaliecosted1 https://t.co/MxsOBDhytX https://t.co/9F4EUtGqOs
-
-
Mashup Score: 26
In this large cohort of pregnant women with SLE, hydroxychloroquine exposure in early pregnancy was associated with a lower pre-eclampsia risk. However, the association with pre-term delivery was unclear.
Source: www.thelancet.comCategories: General Medicine News, RheumatologyTweet-
NEW RESEARCH—Exposure to #hydroxychloroquine in early #pregnancy and incidence of pre-eclampsia and pre-term delivery in patients with systemic lupus erythematosus in Sweden: a nationwide population-based cohort study https://t.co/voBlfHU6MJ https://t.co/pvVKAhX7do
-
-
Mashup Score: 13
The findings of this study suggest a dose-dependent response with CPL’116, with significant efficacy at the high dose of 240 mg twice daily. The drug was generally well tolerated and was not associated with lipid abnormalities or creatinine kinase increase. These findings warrant further investigation in larger studies and different clinical settings.
Source: www.thelancet.comCategories: General Medicine News, RheumatologyTweet-
🔥Hot off the press for #EULAR2025 🔥 Dual JAK and ROCK inhibition with CPL'116 in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomised, double-blind, placebo-controlled, phase 2 trial https://t.co/BMGnp84bGN https://t.co/eJAmVMogZw
-
-
Mashup Score: 0
Rheumatoid arthritis is a chronic inflammatory disorder characterised by joint damage and systemic manifestations.1 It is frequently accompanied by comorbidities and extra-articular features, including cardiovascular disease and pulmonary involvement, both of which are pivotal in informing therapeutic strategies.1 Since the introduction of targeted synthetic disease-modifying antirheumatic drugs (DMARDs), including Janus kinase (JAK) inhibitors in 2019, the therapeutic landscape of rheumatoid arthritis has been substantially altered.
Source: www.thelancet.comCategories: General Medicine News, RheumatologyTweet-
Dual JAK and ROCK inhibition and comorbidities in rheumatoid arthritis Linked Comment by Fabiola Atzeni & @drjamesgalloway https://t.co/XIRB7ESwNl https://t.co/7mSWPvhZc6
-
-
Mashup Score: 13
The findings of this study suggest a dose-dependent response with CPL’116, with significant efficacy at the high dose of 240 mg twice daily. The drug was generally well tolerated and was not associated with lipid abnormalities or creatinine kinase increase. These findings warrant further investigation in larger studies and different clinical settings.
Source: www.thelancet.comCategories: General Medicine News, RheumatologyTweet-
🔥Hot off the press for #EULAR2025 🔥 Dual JAK and ROCK inhibition with CPL'116 in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomised, double-blind, placebo-controlled, phase 2 trial https://t.co/BMGnp84bGN https://t.co/eJAmVMogZw
-
-
Mashup Score: 1About The Lancet Rheumatology - 5 day(s) ago
About
Source: www.thelancet.comCategories: General Medicine News, RheumatologyTweet-
Attending the 45th Korean College of Rheumatology Annual Scientific Meeting next week? Anna Clark, Editor-in-Chief, invites you to reach out with enquiries. Explore our scope, reach & impact, commitment to publishing excellence, & more: https://t.co/3XZXg0rEex https://t.co/UnHEKWs4sZ
-
-
Mashup Score: 18Fabian Müller and Melanie Hagen on a newly discovered toxicity of CD-19 targeting CAR T-cell therapy - 6 day(s) ago
Podcast Episode · The Lancet Rheumatology in conversation with · 06/03/2025 · 21m
Source: podcasts.apple.comCategories: General Medicine News, RheumatologyTweet-
NEW podcast episode🎧 In the third episode of our mini series on cell-based therapies we spoke with Fabian Müller and Melanie Hagen about a newly discovered toxicity of CD19 targeting CAR T-cell therapy Listen🍎https://t.co/5Gf2SpT2gJ or spotify https://t.co/GMdhETKw8D
-
-
Mashup Score: 135Towards precision medicine in antiphospholipid syndrome - 9 day(s) ago
Antiphospholipid syndrome is a rare systemic autoimmune disorder with complex pathophysiology and high heterogeneity in clinical presentation and treatment responses. The core idea of precision medicine is that the varying treatment responses among patients with the same clinical diagnosis are due to differences in their underlying pathogenetic mechanisms and genetic makeup. A better understanding of the pathophysiology and multiple clinical subtypes of antiphospholipid syndrome has led to better classification and subphenotyping of the syndrome.
Source: www.thelancet.comCategories: General Medicine News, RheumatologyTweet-
NEW REVIEW—Towards precision medicine in antiphospholipid syndrome https://t.co/p1sUJvLevk https://t.co/sPIKDYjIsf
-
-
Mashup Score: 126Towards precision medicine in antiphospholipid syndrome - 9 day(s) ago
Antiphospholipid syndrome is a rare systemic autoimmune disorder with complex pathophysiology and high heterogeneity in clinical presentation and treatment responses. The core idea of precision medicine is that the varying treatment responses among patients with the same clinical diagnosis are due to differences in their underlying pathogenetic mechanisms and genetic makeup. A better understanding of the pathophysiology and multiple clinical subtypes of antiphospholipid syndrome has led to better classification and subphenotyping of the syndrome.
Source: www.thelancet.comCategories: General Medicine News, RheumatologyTweet-
NEW REVIEW—Towards precision medicine in antiphospholipid syndrome https://t.co/p1sUJvLevk https://t.co/sPIKDYjIsf
-
NEW for #LUPUS2025—@ern_reconnet–SLICC–@SLEuroSociety expert consensus on the therapeutic management of rare systemic #lupus erythematosus manifestations https://t.co/XwAHpsho57 Free to read with registration on https://t.co/28wkm5ab69 (also free) @Lupusreference #SLE https://t.co/73K0DKTHye